3 research outputs found

    Spatio-temporal Change in Land Use and Land Cover: Implications for Conservation of Fina Faunal Reserve in Mali

    No full text
    The natural resources in FINA reserve of Mali are undergoing intense degradation coupled with increased  human pressure on the reserve. Vegetation in this reserve is severely threatened. Existing inventories  regarding such threats are currently out dated. There is, therefore, a crucial need to assess land use and land  cover change in the reserve. The methodological approach in this study has combined LULC change detection  with LULC intensity analysis. Using Landsat images, intensity analysis model was utilised in detecting  changes in land use and land cover in the reserve, and the changes were evaluated in relation to agricultural  activities in the reserve. The results revealed an increase in agricultural land by 2-4% per annum and a  decrease in savannah wood land by 2% per year from 1985 to 2013. Bare land and Savannah woodland were  found to be gradually replaced by agricultural land. The observed transition of vegetation cover to agricultural  land indicates the extent of human pressure on the reserve. Consequently, to preserve these ecosystems,  there is the need to initiate and implement measures aimed at limiting cultivation and other human activities  in the reserve. These measures should integrate food production and forestry, as well as involve rural  community participation through appropriate incentives.Keywords: Land Use and Land Cover Change, Category Level Analysis, Vegetation Dynamics, Fina faunal reserve

    Seasonal Malaria Chemoprevention Therapy in Children Up To 9 Years of Age: Protocol for a Cluster-Randomized Trial Study

    No full text
    BackgroundSeasonal malaria chemoprevention (SMC) is recommended by the World Health Organization for the sub-Sahel region in sub-Saharan Africa for preventing malaria in children 3 months old to younger than 5 years. Since 2016, the Malian National Malaria Control Program has deployed SMC countrywide during its high malaria transmission season at a rate of 4 monthly cycles annually. The standard SMC regimen includes sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ). Resistance against SP is suspected to be rising across West Africa; therefore, assessing the effectiveness of an alternative antimalarial drug for SMC is needed to provide a second-line regimen when it is ultimately needed. It is not well understood whether SMC effectively prevents malaria in children aged 5 years or older. ObjectiveThe primary goal of the study is to compare 2 SMC regimens (SP-AQ and dihydroartemisinin-piperaquine [DHA-PQ]) in preventing uncomplicated Plasmodium falciparum malaria in children 3 months to 9 years old. Secondly, we will assess the possible use of DHA-PQ as an alternative SMC drug in areas where resistance to SP or AQ may increase following intensive use. MethodsThe study design is a 3-arm cluster-randomized design comparing the SP-AQ and DHA-PQ arms in 2 age groups (younger than 5 years and 5-9 years) and a control group for children aged 5-9 years. Standard SMC (SP-AQ) for children younger than 5 years was provided to the control arm, while SMC with SP-AQ was delivered to children aged 3 months to 9 years (arm 2), and SMC with DHA-PQ will be implemented in study arm 3 for children up to 9 years of age. The study was performed in Mali’s Koulikoro District, a rural area in southwest Mali with historically high malaria transmission rates. The study’s primary outcome is P falciparum incidence for 2 SMC regimens in children up to 9 years of age. Should DHA-PQ provide an acceptable alternative to SP-AQ, a plausible second-line prevention option would be available in the event of SP resistance or drug supply shortages. A significant byproduct of this effort included bolstering district health information systems for rapid identification of severe malaria cases. ResultsThe study began on July 1, 2019. Through November 2022, a total of 4556 children 3 months old to younger than 5 years were enrolled. Data collection ended in spring 2023, and the findings are expected to be published later in early 2024. ConclusionsRoutine evaluation of antimalarial drugs is needed to establish appropriate SMC age targets. The study goals here may impact public health policy and provide alternative therapies in the event of drug shortages or resistance. Trial RegistrationClinicalTrials.gov NCT04149106, https://clinicaltrials.gov/ct2/show/NCT04149106 International Registered Report Identifier (IRRID)DERR1-10.2196/5166
    corecore